Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 9, Issue 7, 2013, Pages 649-657

  Atzeni, Fabiola ^a   Boiardi, Luigi ^b   Sallì, Salvatore ^c   Benucci, Maurizio ^d   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Rheumatology Unit   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Rheumatology Unit   (Italy)

Author keywords

biological agents; computed tomography; disease modifying antirheumatic drugs; interstitial lung disease

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB;

COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG INFILTRATE; PATHOGENESIS; PHYSICAL EXAMINATION; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; ISOXAZOLES; LUNG DISEASES, INTERSTITIAL; METHOTREXATE; PATIENT EDUCATION AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883256994     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.811173     Document Type: Review

References (95)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358(9285), 903-911 (2001).
2. Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr. Opin. Investig. Drugs 10(11), 1204-1211 (2009).
3. Young A, Koduri G, Batley M et al.; Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46(2), 350-357 (2007).
4. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol. Int. 25(6), 429-435 (2005).
5. Brown KK. Rheumatoid lung disease. Proc. Am. Thorac. Soc. 4(5), 443-448 (2007).
6. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-Articular manifestations in rheumatoid arthritis. Ann. Rheum. Dis. 66(1), 59-64 (2007).
7. Nyhäll-Wåhlin BM, Petersson IF, Nilsson JA, Jacobsson LT, Turesson C; BARFOT study group. High disease activity disability burden and smoking predict severe extra-Articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 48(4), 416-420 (2009).
8. Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J. Rheumatol. 35(6), 995-1001 (2008).
9. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-Articular manifestations in Greek patients with rheumatoid arthritis. Clin. Rheumatol. 27(4), 511-513 (2008).
10. Aubart F, Crestani B, Nicaise-Roland P et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J. Rheumatol. 38(6), 979-982 (2011).
11. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod. Rheumatol. 21(2), 164-173 (2011).
12. Vergnenègre A, Pugnere N, Antonini MT et al. Airway obstruction and rheumatoid arthritis. Eur. Respir. J. 10(5), 1072-1078 (1997).
13. Hayakawa H, Sato A, Imokawa S, Toyoshima M, Chida K, Iwata M. Bronchiolar disease in rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 154(5), 1531-1536 (1996).
14. Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis Eur. Respir. J. 7(4), 817-820 (1994).
15. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr. Rheumatol. Rep. 12(5), 363-369 (2010).
16. Gochuico BR, Avila NA, Chow CK et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch. Intern. Med. 168(2), 159-166 (2008).
17. American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 165, 277-304 (2002).
18. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-Associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136(5), 1397-1405 (2009).
19. Lee HK, Kim DS, Yoo B et al. Histopathologic pattern and clinical features of rheumatoid arthritis-Associated interstitial lung disease. Chest 127(6), 2019-2027 (2005).
20. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2(2), 103-121 (2009).
21. Rao RN, Goodman LR, Tomashefski JF Jr. Smoking-related interstitial lung disease. Ann. Diagn. Pathol. 12(6), 445-457 (2008).
22. Pardo A, Gibson K, Cisneros J et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2(9), e251 (2005).
23. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3(4), 357-363 (2006).
24. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56(8), 622-627 (2001).
25. Tanaka N, Kim JS, Newell JD et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232(1), 81-91 (2004).
26. Akira M, Sakatani M, Hara H. Thinsection CT findings in rheumatoid arthritis-Associated lung disease: CT patterns and their courses. J. Comput. Assist. Tomogr. 23(6), 941-948 (1999).
27. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur. Radiol. 14(2), 272-280 (2004).
28. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin. Biochem. 41(13), 1074-1077 (2008).
29. Bongartz T, Cantaert T, Atkins SR et al. Citrullination in extra-Articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 46(1), 70-75 (2007).
30. Atkins SR, Turesson C, Myers JL et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-Associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 54(2), 635-641 (2006).
31. Turesson C, Matteson EL, Colby TV et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-Associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 52(1), 73-79 (2005).
32. Hamblin MJ, Horton MR. Rheumatoid arthritis-Associated interstitial lung disease: diagnostic dilemma. Pulm. Med. 2011, 872120 (2011).
33. Emery P. Early arthritis. In: Targeted Therapies in Rheumatology. Smolen JS, Lipsky PE (Eds). Martin Dunitz, London, UK, 509-513 (2003).
34. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 43(7), 906-914 (2004).
35. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010).
36. Caporali R, Pallavicini FB, Filippini M et al. Treatment of rheumatoid arthritis with anti-TNF-Agents: a reappraisal. Autoimmun. Rev. 8(3), 274-280 (2009).
37. Atzeni F, Benucci M, Sallì S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun. Rev. 12(5), 575-579 (2013).
38. Atzeni F, Sarzi-Puttini P, Gorla R, Marchesoni A, Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun. Rev. 10(7), 397-403 (2011).
39. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford). 41(3), 262-267 (2002).
40. Herrinton LJ, Harrold LR, Liu L et al. Association between anti-TNF-A therapy and interstitial lung disease. Pharmacoepidemiol. Drug Saf. 22(4), 394-402 (2013).
41. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr. Opin. Pulm. Med. 17(5), 362-367 (2011).
42. Kremer JM, Alarcón GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexateassociated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 40(10), 1829-1837 (1997).
43. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 54(5), 1435-1439 (2006).
44. Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-Associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch. Intern. Med. 152(7), 1521-1524 (1992).
45. Turner-Warwick M. Adverse reactions affecting the lung: possible association with D-penicillamine. J. Rheumatol. Suppl. 7, 166-168 (1981).
46. Eastmond CJ. Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis. Br. Med. J. 1(6024), 1506 (1976).
47. Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am. J. Respir. Crit. Care Med. 155(3), 1011-1020 (1997).
48. Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 47(11), 1647-1650 (2008).
49. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol. Int. 15(5), 195-200 (1996).
50. Beyeler C, Jordi B, Gerber NJ, Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br. J. Rheumatol. 35(5), 446-452 (1996).
51. Dayton CS, Schwartz DA, Sprince NL et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 151(4), 1189-1193 (1995).
52. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 43(2), 143-147 (2004).
53. Alarcón GS, Kremer JM, Macaluso M et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann. Intern. Med. 127(5), 356-364 (1997).
54. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J. Rheumatol. 22(6), 1043-1047 (1995).
55. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. 15(2), 373-381 (2000).
56. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexateinduced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin. Rheumatol. 16(3), 296-304 (1997).
57. Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 109(4), 933-938 (1996).
58. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin. Arthritis Rheum. 16(3), 186-195 (1987).
59. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 363, 461 (2004).
60. Chakravarty K, McDonald H, Pullar T et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group; British Association of Dermatologists (BAD). BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 47(6), 924-925 (2008).
61. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 48(9), 1065-1068 (2009).
62. Atzeni F, Talotta R, Salaffi F et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12(7), 703-708 (2013).
63. Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 16(4), 172-174 (2010).
64. Huggett MT, Armstrong R. Adalimumabassociated pulmonary fibrosis. Rheumatology (Oxford) 45(10), 1312-1313 (2006).
65. Taki H, Kawagishi Y, Shinoda K et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol. Int. 30(2), 275-276 (2009).
66. Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol. Int. 1007, 1350-1354 (2010).
67. Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-Associated interstitial pneumonia with rheumatoid arthritis. Mod. Rheumatol. 20(5), 518-521 (2010).
68. Jackson RM, Fell CD. Etanercept for idiopathic pulmonary fibrosis: lessons on clinical trial design. Am. J. Respir. Crit. Care Med. 178(9), 889-891 (2008).
69. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 55(1), 157-159 (2006).
70. Atzeni F, Sarzi-Puttini P. Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Rev. Clin. Immunol. 8(3), 213-222 (2012).
71. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-Associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 69(6), 1086-1091 (2010).
72. Perez-Alvarez P, Perez-de-Lis M, Diaz-Lagares C et al. Interstitial lung disease induced or exacerbated by TNF targeted therapies: analysis of 122 cases. Sem. Arthritis Rheum. 41, 256-264 (2011).
73. Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod. Rheumatol. 22(4), 498-508 (2012).
74. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(2), 189-194 (2008).
75. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur. Respir. J. 24(4), 708 (2004).
76. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritisassociated pulmonary fibrosis to tumor necrosis factor-inhibition. Chest 122(3), 1093-1096 (2002).
77. Antoniou KM, Mamoulaki M, Malagari K et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25(1), 23-28 (2007).
78. Miyazaki Y, Araki K, Vesin C et al. Expression of a tumor necrosis factor-transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96(1), 250-259 (1995).
79. Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR. TNF-induces TGF-1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J. Cell. Mol. Med. 13(8B), 1866-1876 (2009).
80. Kouba DJ, Chung KY, Nishiyama T et al. Nuclear factor-kB mediates TNF-inhibitory effect on 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J. Immunol. 162(7), 4226-4234 (1999).
81. Atzeni F, Doria A, Turiel M, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis Autoimmun. Rev. 6(8), 553-558 (2007).
82. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am. J. Hematol. 82(10), 916-919 (2007).
83. Dass S, Atzeni F, Vital E et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Annals Rheum. Dis. Abstract OP0016 (2001).
84. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46(4), 626-630 (2007).
85. Matteson EL, Bongartz T, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-Associated interstitial pneumonia. Open J. Rheumatol. Autoimmun. Dis. 2, 53-58 (2012).
86. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in rheumatoid arthritis. Autoim. Rev. (2013).
87. Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 20(3), 340-346 (2008).
88. Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther. Adv. Chronic Dis. 4(1), 15-21 (2013).
89. Kawashiri SY, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol. Int. 32(12), 4023-4026 (2012).
90. Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue diseaserelated interstitial lung disease. Chest 130(1), 30-36 (2006).
91. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch. Intern. Med. 168(15), 1718-1719 (2008).
92. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J. Korean Med. Sci. 17(2), 270-273 (2002).
93. Ogawa D, Hashimoto H, Wada J et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 39(12), 1422-1424 (2000).
94. Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand. J. Rheumatol. 40(5), 400-401 (2011).
95. Volpicelli G. Lung sonography. J. Ultrasound Med. 32(1), 165-171 (2013).